A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab Compared to Investigators Choice of Chemoimmunotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation
Study of Acalabrutinib (ACP-196) in Combination with Venetoclax with and without Obinutuzumab in Subjects with Chronic Lymphocytic Leukemia
Sponsor: Acerta Pharma BV
Enrolling: Male and Female Patients
IRB Number: AAAS5165
U.S. Govt. ID: NCT03836261
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study, which involves research, is to determine if giving an experimental drug called acalabrutinib in combination with venetoclax with and without obinutuzumab is safe and effective for treating people with CLL compared to a combination of bendamustine and rituximab (BR) or a combination of Fludarabine, Cyclophosphamide and Rituximab (FCR).
This study is closed
Investigator
Nicole Lamanna, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Have you been diagnosed with Chronic Lymphocytic Leukemia (CLL)? Yes No
Are you able to swallow capsules and tablets without difficulty? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE